entinostat and mk-1775
entinostat has been researched along with mk-1775 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Hoffmann, MJ; Hommel, K; Meneceur, S; Niegisch, G; Schulz, WA | 1 |
Other Studies
2 other study(ies) available for entinostat and mk-1775
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.
Topics: Acrylamides; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Depsipeptides; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Genes, cdc; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Phenylenediamines; Pyrazoles; Pyridines; Pyrimidinones; Urinary Bladder Neoplasms | 2021 |